Joan Merrill, M.D., is a recipient of the 2018 ACR Master designation, one of the highest honors members can receive.
Oblato, Inc., has acquired all rights from OMRF to OKN-007, an investigational drug for the treatment of a deadly form of brain cancer.
Two grants will enable OMRF scientists to examine genes thought to play a role in lupus.
The grants will support more than 50 research and clinical projects, purchase scientific equipment and fund recruitment.
The goal of the new white paper is to create a dramatic shift in how lupus clinical trials are conducted so effective treatments can stand a chance to succeed.
The foundation hopes to recruit up to 2,000 healthy individuals.